Tag: Cancer: Lymphoma
Many With Relapsed/Refractory Lymphoma in Pregnancy Delay Treatment
Five of 23 women studied received intentional antenatal therapy; no malformations or genetic diseases observed
Epkinly Granted Accelerated FDA Approval for Lymphoma
Approved for use in relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
Small Increase in Lymphoma Risk Seen With Crohn Disease, Ulcerative Colitis
Hazard ratios highest for patients exposed to immunomodulators and biologics or second-line biologics
Cancer Risk Increased With Exposure to Four or More CT Scans by Age 18
Increased risk of intracranial tumors, leukemia, and lymphoma by age 25 seen with exposure to four or more CT scans during childhood
Interferon Alfa-2b Effective for Low-Grade Lymphomatoid Granulomatosis
61 percent of patients had complete response to interferon alfa-2b; patients with high-grade disease showed expected response to chemo
Outcomes for R-CHOP Worse in Morning for Female Patients With Lymphoma
Progression-free, overall survival significantly lower for female patients receiving chemo mostly in morning
FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
The next-generation BTK inhibitor zanubrutinib showed greater progression-free survival and fewer side effects in phase 3 trial
Delay in Time to Antibiotics Permissible for Inpatient Neutropenic Fever
Time to antibiotics does not significantly affect overall survival at 180 days in patients with hematologic malignancy who develop inpatient neutropenic fever
ASH: Glofitamab Aids Relapsed, Refractory Diffuse Large B-Cell Lymphoma
39 percent of patients had a complete response, with median time to complete response of 42 days
Brentuximab Vedotin + Chemo Ups Event-Free Survival in Peds Hodgkin Lymphoma
Event-free survival rate higher in pediatric patients, but no difference seen in the percentage of patients receiving involved-site radiation therapy
